Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab

Ioannis Tomazos, J. Rafael Sierra, Karissa M. Johnston, Antoinette Cheung, Robert A. Brodsky, Ilene C. Weitz

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Although complement inhibition is highly effective, patients with paroxysmal nocturnal hemoglobinuria (PNH) may experience intravascular breakthrough hemolysis (BTH). Underlying causes may include elevated free C5, pregnancy, or non-pregnancy complement-activating conditions (e.g. infections). This study compared BTH-related resource utilization and costs in PNH patients treated with eculizumab versus ravulizumab. Methods: A cost model was developed using data from a targeted literature review and a survey of experienced clinicians. Costs associated with BTH episodes were calculated by cause and weighted by the proportion attributed to each cause and the cost of treating each episode. The model captured direct medical costs in 2018 US dollars. Annual BTH-related healthcare resource utilization was also calculated. Results: BTH episodes in the literature were commonly associated with elevated lactate dehydrogenase and aspartate aminotransferase, hemoglobinuria, transfusion needs, and/or recurrence of PNH symptoms. The majority of BTH management costs in eculizumab-treated patients related to changing from the approved dosing regimen following an episode of BTH, rather than acute management. No ongoing dosing changes were expected for ravulizumab-treated patients following episodes of BTH, substantially reducing its ongoing management costs. Resource utilization was greater for eculizumab-treated patients than ravulizumab-treated patients due to higher incidence of BTH, and risk of elevated free C5-related BTH. Total incremental cost was substantially lower for ravulizumab- vs eculizumab-treated patients ($407 vs $9379); results were consistent when pregnant women were not included ($386 vs $3472). Conclusion: Overall resource use and costs for BTH are estimated to be lower for PNH patients receiving ravulizumab compared with eculizumab.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalHematology
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • Breakthrough hemolysis
  • anti-C5 monoclonal antibody
  • complement inhibitor
  • eculizumab
  • healthcare resource utilization
  • medical costs
  • paroxysmal nocturnal hemoglobinuria
  • ravulizumab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab'. Together they form a unique fingerprint.

Cite this